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Background: MRI-only radiotherapy will eliminate the systematic registration errors introduced when transferring
MRI information to the CT. However, challenges concerning the missing information on electron density, necessary
for dose calculation and patient setup on bony anatomy are introduced. This study presents a possible statistical
approach to evaluate, if deviations based on MRI-only radiotherapy as compared to the CT based radiotherapy are
acceptable.
Methods: 18 head-and-neck, 21 prostate, 10 vesica and 8 pelvic patients were included in the study. Data from
each patient contained a CT and a T2-weighted MRI scan, a structure set and a clinically approved CT based
treatment plan, which was re-calculated with identical parameters on the density corrected MRI scans. A statistical
analysis including a 95% confidence interval was performed in clinically relevant DVH points.
Results: The mean differences in the investigated DVH points were in the order of 1.5% for the PTV and up to 4.2%
for organs at risk. In addition, a proposed criterion of 2% dose difference in the PTV coverage for 95% of the
patients was fulfilled for all diagnostic groups for a bulk segmented MRI in the DVH points, Dmedian and D2%, while
only head-and-neck and prostate further fulfilled the criterion in D98%.
Conclusion: Here, we suggested a method for establishing a reliable use of MRI-only radiotherapy. A population-based
study comparing CT based dose calculations with those obtained on a suggested segmentation of MRI should be
initiated and acceptable deviations in clinically relevant DVH points should be established. Such a population-based
approach could form a part of the clinical commissioning of MRI-only radiotherapy.Introduction
The gold standard for radiotherapy (RT) planning is com-
puted tomography (CT). However, little discrimination be-
tween the soft tissues is obtained from the CT, since
tumour and the organs at risk (OARs) have similar attenu-
ation coefficients. Magnetic resonance imaging (MRI) is
therefore increasingly combined with CT for a better delin-
eation of the tumour and OARs. MRI has proven beneficial
for multiple treatment sites such as head-and-neck (HN),
prostate, pelvic and brain [1-4].
Transferring the MRI delineated structures to the CT
scan requires a registration between the two modalities.
This introduces a systematic registration error arising
from deformable anatomical changes and inconsistent pa-
tient setup at the MRI and CT scan. For example, different* Correspondence: marie.elgaard@gmail.com
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reproduction in any medium, provided the orrectal and bladder filling could cause a relative deform-
ation of the prostate, and an imperfect setup of HN pa-
tients could result in different bending of the neck. The
net result is that (ideally non-distorted) MRI delineations
with one relative relationship between structures are
transferred to the anatomy of the CT scan with a different
relative relationship between the structures on which the
treatment is planned. Systematic registration errors have
been quantified for prostate approx. 2 mm (average dis-
placement) [5], rectum approx. 2 mm (average displace-
ment) [6] and head 1.8 ± 2.2 mm (average displacement
and one standard deviation) [7].
An alternative to the CT based RT is so-called MRI-
only RT, where MRI is the only modality in all steps of the
treatment workflow. It has been demonstrated that an
MRI-only simulation can reduce spatial systematic uncer-
tainties by 2 mm compared to a CT based workflow for
prostate patients [8]. MRI-only RT can potentially lead to
a simplified workflow reducing workload and cost [9],ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The different density corrected MRIs for a HN patient.
Left: A homogeneous density assigned MRI. Middle: A bulk density
assigned MRI. Right: A bulk density assigned MRI including air cavities.
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especially in palliative cases. Additionally, MRI-only based
RT enables the use of co-registered functional MRI for as-
sessment of treatment response and adaptive RT [10], and
recently, it introduces the possibility of real-time MRI-
guided RT [11]. The main challenges for MRI-only RT are
geometrical distortion and the lack of the electron density
information needed for dose calculation and setup verifi-
cation on bone [12].
The dosimetric impact of performing dose calculations
on MRI as compared to CT has previously been reported,
although these differences are somewhat inconsistently
described. Kristensen et al. observed a 2% difference for
brain tumours in the prescribed dose region while larger
differences were observed for volumes enclosed by lower
iso-dose levels [13]. Jonsson et al. reported mean differ-
ences in monitor units (MUs) of 0.2% with a standard de-
viation of 0.5 for the prescription point for different MRI
bulk density corrected geometries of prostate and thorax
patients [12]. Lambert et al. reached a mean difference of
approximately 2% for the prostate using a similar ap-
proach [14]. These studies used conventional (non-IMRT)
techniques and did not present any quantitative measure
to determine whether the differences were acceptable in a
more general setting.
With MRI-only based RT, no comparison of the ob-
tained dose distribution with CT is available, and hence,
the order of the dosimetric uncertainty for a patient is un-
known and might be unacceptable, e.g. for a serial OAR.
One way to evaluate the reliability of MRI-only based RT
would be to state a 95%-probability that a patient has an
acceptable maximum deviation from the CT calculated
dose distribution for clinical relevant DVH points or uni-
form equivalent dose conversions.
Here, we present a statistical framework as a possible
tool to decide whether deviations based on MRI-only RT
as compared to standard CT are of an acceptable order.
To illustrate the method, data from dose calculations on
MRI scans as compared to CT are investigated for three
DVH points of the PTV as recommended by ICRU Report
83 [15]. The results are reported for multiple treatment
sites and techniques.
Methods
Retrospective data from 18 HN patients (with oro- and
hypo-pharyngeal cancer) treated with a static intensity-
modulated radiotherapy (IMRT) setup, 21 prostate, 10
vesica and 8 pelvic (not prostate or vesica) patients
treated with volumetric modulated arc therapy (VMAT)
were included. Each patient had a CT-scan (Philips Big
Bore CT), a T2 weighted MRI (Philips 1 T Panorama),
an MRI delineated structure set including targets and
OARs and a clinically approved treatment plan (Eclipse
version 10.0, Varian Medical Systems).MRI-only based dose calculations were performed with
different uniform density corrections, displayed in Figure 1.
 A homogeneous density assigned MRI (MRIu) where
the entire body was assigned the electron density of
water (Hounsfield unit (HU) =0).
 A bulk heterogeneous density assigned MRI (MRIb)
where, in addition, the CT delineated bone was
transferred to the MRI and assigned a bone specific
electron density.
For the vesica-, prostate- and pelvic patients the
assigned electron density was based on the average
age of each diagnostic group. For the HN patients,
an age-independent electron density was assigned
according to skeleton cranium. Table 1 displays an
overview of the electron densities and the corre-
sponding calculated HUs.
 An additional bulk heterogeneous density assigned
MRI (MRIb,c) for the HN patients where the effect
of air cavities was investigated. Here, CT-delineated
air cavities were transferred to the MRI and assigned
the electron density equal to that of air. The effect
of gas pockets in the bowels was not investigated,
since these pockets have an irreproducible interfrac-
tional variation in amount and location.
Prior to the MRI-only based dose calculation, the CT
based treatment plan and structures (bone and cavity)
were registered to the corresponding MRI. The body
was outlined separately on the MRI to include possible
effects of geometrical distortion. The dose distribution
was re-calculated on the density corrected MRI keeping
the CT planning parameters, i.e. photon fluence, beam
energies, angles, MLC control points, monitor units
(MUs) etc. unchanged.
To test if such a CT based re-calculation accurately rep-
resents the dose differences present when only MR images
are available, 10 prostate treatment plans were optimized
Table 1 The calculated Hounsfield units for bone
Diagnostic group Bone tissue Electron density [g/cm3] Calculated HU (age)
HN Skeleton-cranium (whole) 1.61 (adult) 971
Prostate Skeleton-femur (whole) 1.33 (30 years) 349 (66.8 years*)
1.22 (90 years)
Pelvic Skeleton-femur (whole) 1.33 (30 years) 356 (64.7 years*)
1.22 (90 years)
Vesica Skeleton-femur (whole) 1.33 (30 years) 309 (78.8 years*)
1.22 (90 years)
The bone HUs are calculated based on generic electron densities from ICRU Report 46 [16] and a parameterization of our CT calibration curve from ICRU Report
42 [17]. *The average age in the diagnostic group.
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calculated on CT with unchanged MRI planning parame-
ters. Subsequently, no significant change in the observed
dose difference between the CT- and MRI-planning ap-
proaches could be identified for the investigated DVH
points. Therefore, the re-calculation on MRI with un-
changed CT planning parameters was found to be
appropriate.
DVH point investigation
The CT and MRI based dose distributions were compared
in a number of relevant DVH points including the PTV
coverage recommended in ICRU Report 83 [15]. The PTV
DVH points were the near-maximum absorbed dose
(D2%), the near minimum absorbed dose (D98%) and the
median absorbed dose (Dmedian). Elective target volumes
such as lymph nodes were not included in the investiga-
tion. In addition, DVH points for different OARs were
compared. The investigated OARs and corresponding
DVH points were based on the clinical guidelines used in
our department.
Statistical analysis
We adopt a statistical approach on the dose coverage of a
patient cohort as a measure of the reliability of MRI-only
RT. We state that 95% of the patients receiving MRI-only
RT should have an uncertainty on the dose calculation of
the PTV coverage within 2% with respect to that of CT.
Such statistical considerations have previously been ac-
cepted and incorporated into clinical practice on PTV
margin calculations [18]. Ahnesjö et al. presented a table
for the individual components contributing to the overall
uncertainty of delivering RT [19]. If the uncertainty is 1%
and 2% on the CT and MRI dose calculation, respectively,
the uncertainty contribution in dose calculation will be
2.2% adding the errors in quadrature. The resulting overall
uncertainty would then be 3.3%, which we here considered
acceptable.
A statistical analysis comparing the density corrected
MRI versus CT based dose calculations for each diag-
nostic group was carried out to establish 95% confidenceintervals (CI) and test the influence of significance (sig-
nificance level α = 0.05). An univariate analysis of variance
(ANOVA) was performed with an one-way two-tailed
ANOVA using the statistical software R version 2.11.0 [20].
If the ANOVA displayed a significant difference, a pair wise
means comparison was performed with a TukeyHSD ana-
lysis for further investigation [21]. The TukeyHSD de-
creases the risk of detecting a false positive result, i.e.
significance, as compared to a t-test. Prior to the statistical
analysis, the data were tested and found to be independent
and approximately normally distributed with constant vari-
ances thereby fulfilling the assumptions of the chosen
statistical methods. The dosimetric differences will be pre-
sented as percentage difference with respect to CT ± two
standard deviations thereby describing the approximate
95% CI of the differences. The CIs were based on the stand-
ard deviations calculated from the individual diagnostic
groups and not from the pooled data of the ANOVA.
The investigation of rectum for the prostate patients
was split into two groups since the prescribed dose
showed to be significant in a two-way two-tailed ANOVA.
This is a non-interventional retrospective study assur-
ing the quality of treatment using different image modal-
ities. According to the National Health Research Ethics
Committee in Denmark (DNVK), such a study does not
require an ethics approval.
Results
The percentage differences between the DVH points from
the CT and the density corrected MRIs are displayed in
Table 2. In general, the mean percentage differences for
PTV coverage were in the order of 1.5%, which is in agree-
ment with results previously reported. The percentage dif-
ferences for OARs were up to 4.2% and no statistical
difference could be detected for the investigated OARs. In
97% of the investigated DVH points, non-significant dif-
ferences had p-values above 0.1.
Prostate patients
Investigation of the PTV for the prostate patients
showed that MRIb gave results significantly closer to CT
Table 2 Statistical results of the DVH point analysis
Diagnostic group Volume (# of patients) DVH point MRIu [%] MRIb [%] MRIb,c [%] Significance (p-value)
Prostate PTV (21) Dmedian 1.3 ± 1.4 −0.0002 ± 1.1 - A(0.0), B(0.0)
D98% 1.4 ±1.9 −0.03 ± 1.7 - A(0.01), B(0.0008)
D2% 1.4 ± 1.3 −0.02 ± 1.0 - A(1.0 · 10
-7), B(0.0)
Rectum* (12) D10% 2.0 ± 1.7 0.6 ± 1.6 - NS
D30% 1.9 ± 2.5 0.8 ± 2.5 - NS
D60% 1.0 ±3.0 0.2 ± 3.0 - NS
Rectum* *(9) D10% 2.2 ± 3.0 0.9 ±3.0 - NS
D30% 0.8 ± 1.5 −0.008 ± 1.3 - NS
D60% −0.06 ± 1.6 −0.7 ± 1.6 - NS
HN PTV (18) Dmedian 1.0 ± 1.9 −0.6 ± 1.2 −0.02 ± 3.0 B(0.02)
D98% 1.6 ± 2.3 −0.006 ± 1.8 −1.0 ± 2.8 C(0.005)
D2% 1.2 ± 2.0 −0.4 ± 0.9 0.4 ± 4.3 B(0.04)
Medulla (18) Dmax 0.8 ± 3.6 −1.4 ± 3.8 −1.4 ± 3.6 NS
Parotid sin (16) Dmean −1.2 ± 6.8 2.5 ± 7.4 −1.3 ± 8.7 NS
Parotid dxt (16) Dmean 1.7 ± 7.4 0.2 ± 6.8 1.4 ± 8.9 NS
Vesica PTV (10) Dmedian 0.4 ± 1.2 −0.3 ± 1.3 - B(0.008)
D98% −0.9 ± 4.8 −1.4 ± 4.2 - NS
D2% 1.1 ± 1.5 0.2 ± 1.8 - A(0.05)
Rectum (10) D2cm
3 0.7 ± 1.6 −0.1 ± 1.7 - NS
V40Gy −0.1 ± 3.0 −0.6 ± 3.2 - NS
Femur sin (10) Dmax 1.4 ± 3.4 −0.6 ± 1.9 - NS
Femur dxt (10) Dmax 0.7 ± 2.0 −0.7 ± 2.0 - NS
Intestine (8) D2cm
3 −0.5 ± 3.5 −0.9 ± 3.4 - NS
V35Gy 4.2 ± 8.0 3.5 ± 7.6 - NS
Pelvic PTV (8) Dmedian −0.2 ± 1.3 −0.3 ± 1.2 - NS
D98% −0.9 ± 2.0 −1.5 ± 2.0 - NS
D2% 0.8 ± 1.4 0.03 ± 1.6 - NS
Femur sin (8) Dmean 0.3 ± 1.1 −0.5 ± 1.3 - NS
Dmax 0.07 ± 1.5 −0.2 ± 3.3 - NS
Femur dxt (8) Dmean 0.1 ± 3.1 −0.2 ± 2.2 - NS
Dmax 0.3 ± 2.5 −0.4 ± 1.4 - NS
The percentage differences of MRIu, MRIb and MRIb,c with respect to CT, in mean value ± two standard deviations corresponding to the approximate 95%
confidence interval. *Prescribed dose of 70 Gy. **Prescribed dose of 78 Gy.
CT vs. MRIu (A), MRIu vs. MRIb (B), MRIu vs. MRIb,c (C). NS = Non-significant.
CT vs. MRIb, CT vs. MRIb,c, and MRIb vs. MRIb,c were also tested.
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PTV from the 21 prostate patients as well as the investi-
gated PTV DVH points. The differences in the selected
DVH points seem to be representative for the differences
in the entire DVH.Vesica patients
The results for the vesica patients showed that MRIu dif-
fered significantly from CT and MRIb in Dmedian and D2%
for PTV, while no statistical differences were seen for the
remaining investigated DVH points within this diagnosis.HN patients
The density corrected MRIs for the PTV in HN patients
showed a significant difference between MRIu and CT,
and, MRIb and MRIb,c respectively. The bulk density cor-
rected MRIs with and without air cavities did not differ re-
markable. No significant differences were seen for the
OARs but a large standard deviation for the parotid glands
could be observed (see Discussion).
Pelvic patients
Neither the PTV nor the OARs showed significance when
comparing the density corrected MRIs with the CT for the
Figure 2 The average DVH for PTV based on 21 prostate
patients. The intersection between the horizontal lines and the
DVHs, is the value of the indicated DVH points.
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seen for the intestines (see Discussion).
In Figure 3, conservative 95% confidence intervals are
plotted versus diagnosis for the PTV DVH points (PTV
coverage). With the bulk density correction for bone, our
segmentation criterion of 2% dose calculation deviation
was reached for all investigated diagnoses for Dmedian and
D2% while only HN and prostate further fulfilled the criter-
ion for D98%. With the unit density correction, only the
vesica and pelvic patients fulfilled the criteria for the Dme-
dian point. Hence, one could state that our bulk density
correction was sufficient for HN and prostate in MRI-only
RT if 95% of the patients should have a dose calculation
uncertainty of 2% or less. On the PTV coverage, no clear
correlation between a significant difference from CT and
passing of the acceptance criteria were found.
Discussion
MRI-only RT receives increasingly attention as MRI be-
comes more integrated into modern RT [22,23]. Further,
evidence of including MRI into new treatment sites is
emerging. Sparing of the hippocampus in cranial irradi-
ation could be one such example that would require anFigure 3 The approximate 95% CI for the dosimetric differences of th
Deviations are plotted in a descending order for the MRIu data. MRIu = uniMRI for palliative treatment otherwise traditionally car-
ried out on CT alone [24]. This raises the question of
when it is clinically acceptable to perform RT based on
MRI as the only modality.
Here, we suggested a method to evaluate the reliability
for introducing MRI-only RT. A population based study
comparing CT based dose calculations with those carried
out on the segmented MRI of choice (e.g. [25]) should be
initiated. Acceptable deviations in clinically relevant DVH
points should be established. In this study we accepted a
2% deviation in PTV coverage for 95% of the patients and
assumed an uncertainty of 1% on the CT based calcula-
tions. If a more conservative uncertainty estimate from
CT based calculations is assumed, e.g. about 3% as esti-
mated by ICRP more than 10 years ago [26], a more re-
stricted uncertainty requirement should be imposed on
the MRI deviation ultimately to reach an overall uncer-
tainty of about 4% [19]. We obtained a conservative CI for
the MRIb medulla of 4.2%, which could be critical near
tolerance doses for myelopathy. Tighter acceptance cri-
teria, e.g. a 1% deviation for a 99% CI could be considered
on normal tissue complication probabilities that receive a
high priority.
The size of the patient cohort will influence the statis-
tical power and therefore the credibility by which a seg-
mentation strategy fulfill a criterion for MRI-only RT. The
size of the patient cohort included in the study can influ-
ence the ability to estimate a dosimetric difference with
acceptable statistical power. A power analysis on the avail-
able CT dose statistics in the relevant DVH points should
therefore be carried out. For example, the D98% mean and
standard deviation for the prostate patients CT based dose
calculation were 1.94 and 0.03 Gy, respectively. With 21
patients, the ability to detect a mean difference of at least
2% could be made with a power of 96%. As seen in the
middle panel of Figure 3, such a calculation did not indi-
cate whether a segmentation criteria for MRI-only RT was
fulfilled for 95% of the patients (bulk passes and unit doese PTV when comparing CT and density corrected MRI.
t. MRIb = bulk.
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lysis. A limitation in the proposed approach was that only
a measure of similarity in the DVH points was described
without any spatial information of where the differences
were located.
Large CIs of 8 and 7% were found for the intestines and
parotid glands, respectively. The former could be due to ir-
reproducible gas pockets, which were not transferred to the
MRI from CT, and were considered less critical. For the lat-
ter, inspections of the CT and MRI showed that the main
differences in the body-outline were in the area around the
ears, which potentially influenced the calculated dose to the
parotid glands. Therefore, this area needs special attention
during MRI acquisition and should possibly be corrected
for geometrical distortion. Generally, OARs are in lower
dose regions and small differences in absolute dose would
appear as larger percentage differences. Therefore, the
standard deviations in general were found to be larger for
the OARs than the PTV DVH points.
The investigation of the HN patients showed similar
results when comparing the bulk density corrected MRIs
with and without air cavities, this may be related to the
fact that no patients with nasopharyngeal cancer, where
the dose distributions are expected to be more influ-
enced by air cavities, were included. Hence, the effect of
air cavities in nasopharyngeal cancer patients should be
investigated further.
For our bulk density correction the majority of the pa-
tients showed an uncertainty of 2% or less, on the PTV
coverage. The patients that did not fulfil the criteria and
their corresponding dose distribution were investigated. For
the D98%, 1 prostate (1/21), 1 HN (1/18), 2 vesica (2/10)
and 2 pelvic (2/8) patients had deviations above 2% which
is consistent with the diagnosis passing the criteria in the
middle panel of Figure 3. For the abdominal area, these pa-
tients had multiple gas pockets leading to dose valleys in
the corresponding MRI dose distributions. The position of
the tumor bed of the (post-surgery) HN patient was close
to the trachea. This was uncorrected for in the MRIb seg-
mentation with a percentage deviation of 2.3% whereas the
deviation was 0.6% in the MRIb,c segmentation. These find-
ings could speak in favor of including air segmentation for
all diagnostic groups although this was not the strategy
chosen in this study. One vesica patient did not meet the
criteria D2%, which could be explained by an abnormally
large change in body outline on MRI as compared to CT
due to an anatomic deformation (interfractional variation).
This study separated the results for the different diag-
nostic groups why the impact of the different delivery
techniques could not be estimated, as each diagnostic
group was treated with the same delivery technique. Since
our main results are consistent with those reported previ-
ously obtained with 3D conformal RT, the impact is ex-
pected to be minimal.Conclusion
We have suggested a method for establishing a reliable
use of MRI-only radiotherapy. A population-based study
comparing CT based dose calculations with those ob-
tained on a suggested segmentation of MRI should be ini-
tiated and acceptable deviations in clinically relevant DVH
points should be established. Such a population-based ap-
proach could form a part of the clinical commissioning of
MRI-only radiotherapy.
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